CVS Health Launches Company To Produce Cheaper Versions of Expensive Biotech Drugs

August 24, 2023

CVS Health has introduced Cordavis, a new subsidiary aimed at producing and commercializing “biosimilar” drugs, which are more affordable versions of costly brand prescriptions derived from biotechnology. Cordavis will collaborate directly with drug manufacturers to develop and distribute these biosimilar products, which are approved by the FDA as highly similar and without clinically meaningful differences from existing brand biologic medicines. CVS aims to ensure a consistent and affordable supply of these biosimilars to enhance patient accessibility to vital treatments while reducing costs.

Recent News

US Plans Tariffs on Chinese Electric Vehicles

The Biden administration intends to announce new tariffs on Chinese electric vehicles (EVs), possibly reaching 100%, along with additional import taxes on various Chinese goods, including semiconductors. This move aims to safeguard American manufacturing interests, amidst concerns that China’s competitive pricing may undermine US efforts to boost domestic clean energy production.